GSK inaugurates Euro 150m Belgian quality control centre
GSK Biologicals, the vaccines arm of GlaxoSmithKline, has inaugurated a new quality control centre in Wavre in Belgium, representing a Euro 150m investment.
GSK Biologicals, the vaccines arm of GlaxoSmithKline, has inaugurated a new quality control centre in Wavre in Belgium, representing a Euro 150m investment.
The new centre is part of GSK's three-year-old investment policy in Belgium. The building, which contains 100 laboratories, will provide quality control for the whole of GSK's vaccine production in Belgium at every stage of production.
The Wavre site aims to become GSK Biologicals' new expansion platform, carrying out worldwide production of new vaccines including Rotarix for rotavirus and Cervarix for cervical cancer. Between 400 and 500 people are expected to work at the centre. As well as the production of the new vaccines and quality control, Wavre will house GSK Biologicals' administrative and support functions.
'Adapting quality control capacity to our future development was crucial,' said GSK Biologicals' president and general manager Jean Stephenne.
GSK Biologicals had announced last year that it would make total investments of €450m to develop this site. In 2006 the group had announced the creation of 600 jobs in Belgium to accompany the launch of five new vaccines in the next five years.